暂无中文译文，显示英文原文。
#Tarlatamab #ESMO26 #SCLC
79 浏览 · 0 赞 · 0 转发 · 1 回复
Sustained survival with extended follow-up of tarlatamab plus anti-PD-L1 as first-line maintenance (1LM) after chemoimmunotherapy for extensive-stage small cell lung cancer (ES-SCLC): DeLLphi-303 phase 1b study
https://esmocongress.esmo.orgCytokine release syndrome in patients receiving tarlatamab for extensive-stage small cell lung cancer: A real-world analysis
https://esmocongress.esmo.orgTarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org@pistoto2017 Very relevant question! Platinum rechallenge or lurbinectedin may be options. But optimal 2L sequencing after tarlatamab maintenance remains an important unanswered question!在 X 查看被引用的帖子
- Cosas De Bolsa@BolsaCosas
@pistoto2017 Cuál es tu opinión FJ? Los resultados han sido bastante buenos, algo mejor de lo esperado, pero dentro de lo normal. Es real esos 21,1 de OS o hay que sumar o restar algún mes por ser en inducción?
来源：FJ ⭐️⭐️+⭐️ · x.com